Isolation and expansion of cytomegalovirus-specific cytotoxic T lymphocytes to clinical scale from a single blood draw using dendritic cells and HLA-tetramers

Blood

Volumn 98, Issue 3, 2001, Pages 505-512

  Szmania, Susann ^a,b,c   Galloway, Amanda ^a,b,c   Bruorton, Mary ^a,b,c   Musk, Philip ^a,b,c   Aubert, Geraldine ^a,b,c   Arthur, Andrew ^a,b,c   Pyle, Haywood ^a,b,c   Hensel, Nancy ^a,b,c   Nga, Ta ^a,b,c   Lamb Jr , Lawrence ^a,b,c   Dodi, Toni ^a,b,c   Madrigal, Alejandro ^a,b,c   Barrett, John ^a,b,c   Henslee Downey, Jean ^a,b,c   Van Rhee, Frits ^a,b,c,d,e  

^a UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^c ANTHONY NOLAN RESEARCH INSTITUTE   (United Kingdom)

^d Department of Medicine ^*  (United States)

^e UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; BETA1 INTEGRIN; CD40 LIGAND; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HLA ANTIGEN; INTEGRIN; INTERLEUKIN 4; PHYCOERYTHRIN;

ADOPTIVE IMMUNOTHERAPY; ANTIGEN EXPRESSION; ARTICLE; BONE MARROW TRANSPLANTATION; CELL ISOLATION; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG INDUCED DISEASE; ENDOTHELIUM CELL; FIBROBLAST; HUMAN; HUMAN CELL; LYMPHOBLASTOID CELL LINE; MONOCYTE; MORBIDITY; MORTALITY; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION; VIRUS PNEUMONIA; VIRUS REACTIVATION;

EID: 0035437133     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V98.3.505     Document Type: Article

References (39)

1. Goodrich JM, Bowden RA, Fisher L, et al. Ganciclovir prophylaxis to prevent cytomegalovirus infection after allogeneic marrow transplant. Ann Intern Med. 1993;118:173-178.
2. Meyers JD, Flournoy N, Thomas ED. Risk factors for cytomegalovirus infection after human marrow transplantation. J Infect Dis. 1986;153:478-488.
3. Weiner RS, Bortin MM, Gale RP, et al. Interstitial pneumonitis after bone marrow transplantation: assessment of risk factors. Ann Intern Med. 1986;104:168-175.
4. Reed EC, Bowden RA, Dandliker PS, et al. Treatment of cytomegalovirus pneumonia with ganciclovir and intravenous immunoglobulin in patients with bone marrow transplant. Ann Intern Med. 1988;109:783-788.
5. Winston DJ, Ho WG, Bartoni K, et al. Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients: results of a placebo-controlled, double-blind trial. Ann Intern Med. 1993;118:179-184.
6. Meyers JD, Reed EC, Shepp DH, et al. Acyclovir for prevention of cytomegalovirus infection and disease after allogeneic marrow transplantation. N Engl J Med. 1988;318:70-75.
7. Prentice HG, Kho P. Clinical strategies for the management of cytomegalovirus infection and disease in allogeneic bone marrow transplant. Bone Marrow Transplant. 1997;19:135-142.
8. Prentice HG, Gluckman E, Powles RL, et al. Impact of long-term acyclovir on cytomegalovirus infection and survival in allogeneic marrow transplantation. Lancet. 1994;343:749-753.
9. Singhal S, Mehta J, Powles R, Treleaven J, et al Horton C. Three weeks of ganciclovir for cytomegaloviraemia after allogeneic bone marrow transplantation. Bone Marrow Transplant. 1995;15:777-781.
10. Boeckh M, Gooley TA, Myerson D, et al. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment: a randomized double-blind study. Blood. 1996;88:4063-4071.
11. Knox KK, Drobyski WR, Carrigan DR. Cytomegalovirus isolate resistant to ganciclovir and foscarnet from a marrow transplant patient. Lancet. 1991;337:1292-1293.
12. Li CR, Greenberg PD, Gilbert MJ, et al. Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: correlation with CMV disease and effect of ganciclovir prophylaxis. Blood. 1994;83:1971-1979.
13. Slavin MA, Bindra RR, Gleaves CA, et al. Ganciclovir sensitivity of cytomegalovirus at diagnosis and during treatment of cytomegalovirus pneumonia in marrow transplant recipients. Antimicrob Agents Chemother. 1993;37:1360-1363.
14. Reusser P, Cordonnier C, Einsele H, et al, for the Infectious Disease Working Party of the European Group for Blood and Marrow Transplantation (EBMT). European survey of herpes virus resistance to antiviral drugs in bone marrow transplant recipients. Bone Marrow Transplant. 1996;17:813-817.
15. Walter EA, Greenberg PD, Gilbert MJ, et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med. 1995;333:1038-1044.
16. Ellis JM, Henson V, Slack R, et al. Frequencies of HLA-A2 alleles in five US population groups. Hum Immunol. 2000;61:334-340.
17. van Rhee F, Szmania S, Arthur A, et al. Cytomegalovirus (CMV) pp65 pulsed dendritic cells (DCs) cultured in autologous plasma can stimulate CMV specific autologous cytotoxic T-lymphocyte responses [abstract]. Blood. 1999;94:332b.
18. Diamond DJ, York J, Sun JY, et al. Development of a candidate HLA-A*0201 restricted peptide-based vaccine against human cytomegalovirus infection. Blood. 1997;90:1751-1767.
19. Solache A, Morgan CL, Dodi AI, et al. Identification of three HLA-A*0201-restricted cytotoxic T cell epitopes in the cytomegalovirus protein pp65 that are conserved between eight strains of the virus. J Immunol. 1999;163:5512-5518.
20. + virus-specific cytotoxic T lymphocytes. J Med Virol. 1994;43:103-110.
21. Beninga J, Kropff B, Mach M. Comparative analysis of fourteen individual human cytomegalovirus proteins for helper T cell response. J Gen Virol. 1995;76:153-160.
22. van Zanten J, Harmsen MC, van der Meer P, et al. Proliferative T cell responses to four human cytomegalovirus (HCMV)-specific proteins in healthy subjects and solid organ transplant recipients. J Infect Dis. 1995;172:879-882.
23. Boppana SB, Britt WJ. Recognition of human cytomegalovirus gene products by HCMV-specific cytotoxic T cells. Virology. 1996;222:293-296.
24. Wills MR, Carmichael AJ, Mynard K, et al. The human cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp65: frequency, specificity, and T-cell recepfor usage of pp65-specific CTL. J Virol. 1996;70:7569-7579.
25. Cereb N, Maye P, Lee S, et al. Locus-specific amplification of HLA class I genes from genomic DNA: locus-specific sequences in the first and third introns of HLA-A, -B, and -C alleles. Tissue Antigens. 1995;45:1-11.
26. Dunbar PR, Chen JL, Chao D, et al. Cutting edge: rapid cloning of tumor specific CTL suitable for adoptive immunotherapy of melanoma. J Immunol. 1999;162:6959-6962.
27. + T cells in melanoma patients. J Immunol. 2000;165:533-538.
28. + T-cells. J Immunol. 2000;164:3950-3954.
29. Musk P, Szmania S, Scott A, et al. Clinical-scale generation of EBV-specific cytotoxic T cells suitable for adoptive immunotherapy of EBV-induced lymphoma post haploidentical bone marrow transplant. J Immunother. In press.
30. Keenan R, Ainsworth J, Assenmacher M, et al. Magnetic selection of cytomegalovirus-specific CTLs for use in antigen-specific donor leukocyte infusion [abstract]. Blood. 1999;94:320a.
31. + T-cells usable in immunotherapy. Nat Biotechnol. 1998;16:281-285.
32. Brosterhus H, Leyendeckers H, Brings S, et al. Analysis and isolation of live antigen-specific T-cells based on cytokine secretion [abstract]. Blood. 1999;94:556a.
33. Sun Q, Pollok KE, Burton RL, et al. Simultaneous ex vivo expansion of cytomegalovirus and Epstein-Barr virus-specific cytotoxic T lymphocytes using B-lymphoblastoid cell lines expressing cytomegalovirus pp65. Blood. 1999;94:3242-3250.
34. Reeves ME, Royal RE, Lam JS, et al. Retroviral transduction of human dendritic cells with a tumor-associated antigen gene. Cancer Res. 1996;56:5672-5677.
35. Keever-Taylor CA, Margolis D, Sandford G, et al. Generation of cytomegalovirus-specific cytolytic T cell lines and clones using pp65 transfected dendritic cells [abstract]. Blood. 1999;94:52a.
36. Zajac AJ, Blattman JN, Murali-Krishna DJ, et al. Viral immune evasion due to persistence of activated T cells without effector function. J Exp Med. 1998;188:2205-2213.
37. Kalams SA, Walker BD. The critical need for CD4 help in maintaining effective cytotoxic T lymphocyte responses. J Exp Med. 1998;188:2199-2204.
38. + T cells produce antiviral cytokines but are impaired in cytolytic function. J Exp Med. 2000;192:63-75.
39. + T cells. J Virol. 2000;74:1018-1022.